Alpha Cognition Receives FDA Approval for Alzheimer's Therapy
Alpha Cognition (ACI) has announced that the U.S. Food and Drug Administration (FDA) has approved ZUNVEYL® (benzgalantamine), previously known as ALPHA-1062, for treating mild-to-moderate Alzheimer's disease (AD). AD is a progressive brain disorder that gradually impairs memory, cognitive skills, and the ability to perform simple tasks, affecting nearly 7 million people and being a primary cause of nursing home admissions and deaths. About 70% of all nursing home residents suffer from AD.
Alpha Cognition Receives FDA Approval for Alzheimer's Therapy